The company that is currently at the top of my to buy list is Anika Therapeutics Inc. (ANIK) I consider the company to be suspiciously cheap but maybe its simply an overlooked small cap. The main reason that so far has prevented me from buying is the lack of buying power at my Datek account.
The most important new product is probably Orthovisc. This is a hyaluronic preparation for the treatment of ostheoarthritis. The Orthovisc PMA has been filed in december.
From Yahoo, Zacks and the companies 10Q files:
sec.gov
Anika Therapeutics, Inc.
Notes to Financial Statements
(1) Nature of Business
Anika Therapeutics, Inc. (the "Company") develops,
manufactures and commercializes therapeutic products and
devices intended to promote the protection and healing of
bone, cartilage and soft tissue These products are based on
hyaluronic acid (HA), a naturally-occurring, biocompatible
polymer found throughout the body. Due to its unique
biophysical and biochemical properties, HA plays an important
role in a number of physiological functions such as the
protection and lubrication of soft tissues and joints, the
maintenance of the structural integrity of tissues, and the
transport of molecules to and within cells. The Company has
been developing HA and HA based products since 1983. The
Company's currently marketed products consist of ORTHOVISC ,
which is an HA product used in the treatment of some forms of
osteoarthritis ("OA") in humans and HYVISC , which is an HA
product used in the treatment of equine osteoarthritis.
ORTHOVISC is currently approved for marketing in Canada and
Europe; in the U.S., ORTHOVISC is limited to investigational
use only. The Company manufactures AMVISC (1) and AMVISC Plus ,
which are HA products used as viscoelastic supplements in
ophthalmic surgery, for Chiron Vision, a subsidiary of Chiron
Corporation. The Company is currently developing INCERT ,
which is an HA based product designed for use in the
prevention of post-surgical adhesions. In addition, the
Company is collaborating with Orquest, Inc. to develop
OSSIGEL , an injectable formulation of basic fibroblast growth
factor combined with HA designed to accelerate the healing of
bone fractures.
Market cap $67.3 million, recent price $8.875, 12 month range $5 - $10.75, Trailing 12 months PE 22.99, PS 1.63
Earnings/share
1997 0.34
1998e 0.32
1999e 0.48
There are currently 2 analyst recommendations as moderate buy. One of them has a 5 year earnings growth estimate of 30%/year.
The SI thread Subject 10956 is not linked to the chart and profile witch is also available under the ticker ANIK.
Andreas |
